MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
7.94
+0.93
+13.27%
Closed 19:02 05/21 EDT
OPEN
6.87
PREV CLOSE
7.01
HIGH
8.53
LOW
6.83
VOLUME
193.97K
TURNOVER
123.19K
52 WEEK HIGH
1,838.76
52 WEEK LOW
6.15
MARKET CAP
6.62M
P/E (TTM)
-0.0060
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAZ last week (0512-0516)?
Weekly Report · 3d ago
Reported May 14, 2025: TransCode Therapeutics Q1 EPS $(2.51) Misses $(2.00) Estimate
Benzinga · 05/15 12:56
Transcode Therapeutics Inc trading halted, news pending
TipRanks · 05/14 23:50
TRANSCODE THERAPEUTICS, INC. Quarterly Report on Form 10-Q
Press release · 05/14 20:32
Weekly Report: what happened at RNAZ last week (0505-0509)?
Weekly Report · 05/12 11:20
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested
TipRanks · 05/11 12:27
Transcode Therapeutics completes dosing of patients in Phase 1a cancer trial
TipRanks · 05/08 12:38
TransCode Therapeutics Faces Nasdaq Delisting Risk
TipRanks · 05/07 21:40
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.